Drug Profile
Nevirapine - Boehringer Ingelheim
Alternative Names: BI-RG-587; BIRG 0587; Extended release nevirapine; Nevirapine ER; Nevirapine XR; NSC 641530; Viramune; Viramune Extended Release; Viramune XRLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Cyclopropanes; Pyridines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
- Phase III HIV infections
Most Recent Events
- 23 May 2012 Generic nevirapine equivalent available in the US for HIV-1 infections
- 07 Feb 2012 Boehringer Ingelheim completes a phase III trial of extended-release nevirapine in HIV-1 infections (treatment-naive) in US, Argentina, Australia, Belgium, Botswana, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russia, South Africa, Spain, Switzerland & UK (NCT00561925)
- 21 Sep 2011 Registered for HIV-1 infections in European Union and in Liechtenstein, Iceland and Norway (PO once-daily, controlled release)